You’re entitled to your view but I don’t agree with it. The...

You’re entitled to your view but I don’t agree with it. The value in this sector is always created in the first instance by IP development, not cash flow.

By way of example, GW Pharma was a US$3 billion company on the back of the success of their Epidiolex clinical trials and that was prior to one single dollar being generated from the drug.

The big “hockey stick” rerate for investors is created by the drug development and its IP.

IHL has five clinical trials underway and a sixth yet to be announced. IMO the opportunity to be leveraged to that price rerate is now when that IP is being created.